A new oral weight loss medication, orforglipron, demonstrated meaningful weight loss results in phase 3 trials, potentially ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Like many GLP-1 medications approved for diabetes, however, weight loss is a side effect of Rybelsus. “Data has shown modest ...

Pharmacy benefit managers are working on a proposal to voluntarily change some business practices in an effort to avoid new ...

But -- finally -- Pfizer is getting into the obesity drug game. This past week, the company announced it will acquire Metsera ...

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a sin | Eli Lilly has pulled the plug on a phase ...

In recent weeks Novo Nordisk has secured several key label expansions for some of its products, which should contribute meaningfully to the company's results. The company's most famous weight ...

New York City doctors reveals how weight-loss drugs reduce inflammatory cytokines by decreasing fat cells, potentially preventing cancer and autoimmune diseases.

Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much ...

Eli Lilly plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the ...

Oral Ozempic alternative Orforglipron inspired the biggest biotech investment in Texas history, in Generation Park.